Yi Zhanmiao
Associate Professor, Chief Pharmacist, Master’s Supervisor
Research Interests: Evidence-Based Pharmacy, Pharmacoeconomics, Artificial Intelligence
Tel: +86-10-82265740
Email: yzm@hsc.pku.edu.cn
EDUCATION
Clinical Research Methods Remote Training Program, University of New York (2021)
Doctor of Science, Peking University (2020)
Clinical Pharmacist Faculty Training Program, Chinese Hospital Association & Peking University (2017)
Delivering Medication Therapy Management Services Faculty Training Program, American Pharmacists Association (AphA) (2017)
Global Health Diploma Program, Duke University–Peking University (2015)
Executive Training Program in Business Administration, Tsinghua University (2014)
Master of Science, Peking University (2011)
Bachelor of Science, Peking University (2009)
PROFESSIONAL EXPERIENCE
2023–2023, University of Manchester
Academic Visitor
2021–present, Department of Pharmacy, Peking University Third Hospital
Associate Professor
2011–present, Department of Pharmacy, Peking University Third Hospital
Pharmacist (2011–2013)
Senior Pharmacist (2013–2018)
Associate Chief Pharmacist (2018–2025)
Chief Pharmacist (2025–present)
ACADEMIC APPOINTMENTS
Secretary, International Practice Guidelines Registry Platform
Member, Expert Committee, International Union of Angiology (IUA), China Branch
Member, Evidence-Based Clinical Pharmacy Group, Evidence-Based Medicine Committee, Chinese Medical Doctor Association
Member, Geriatric Cerebrovascular Disease Branch, Chinese Association of Geriatric Health Care
Member, Committee on Rational Use and Risk Evaluation of Drugs and Devices, China Association of Geriatric Health Care
Expert, National Graduate Education Evaluation and Monitoring Expert Database
Expert, National Science and Technology Expert Database
Advisory Expert, National Demonstration Project on Public Hospital Reform and High-Quality Development
Member, Higher Education Narrative Medicine Practice Alliance
Technical Investigator, Beijing Intellectual Property Court
Review Expert, Beijing Association for Science and Technology Talent Recommendation Program
Review Expert, Science and Technology Project Evaluation Database, Beijing Municipal Science & Technology Commission / Zhongguancun Administrative Committee
Expert, Beijing Medical and Health Science & Technology Innovation Achievement Transformation Database
Standing Committee Member, Medication Therapy Management Committee, Beijing Pharmacists Association
Member, Regulatory Science and Pharmacoeconomics Committee, Beijing Pharmaceutical Society
Member, Anti-infective Pharmacotherapy Committee, Beijing Pharmaceutical Society
Member, Free Radical Committee, Beijing Society for Neuroscience
Part-time Expert, Post-marketing Drug Safety Evaluation Center, Peking University Health Science Center
External Supervisor, Master of Pharmacy Program, China Pharmaceutical University
Reserve Academic Leader, Peking University Third Hospital
Deputy Editor, Young Editorial Board, China Pharmacy (1st & 2nd Terms)
Deputy Editor, Young Editorial Board, Journal of Clinical Drug Therapy
AWARDS AND CERTIFICATES
Outstanding Young Editorial Board Member, China Pharmacy (2024,2025)
Top 5% Most Cited Chinese Scholars, CNKI (2024,2025)
Second Prize, Continuing Education Courseware Competition for Licensed Pharmacists of Jiangsu Province (2023)
Outstanding Pharmacist, Beijing Pharmaceutical Society (2022)
Management Science Award, Chinese Society of Management Science (Ranked 5/8) (2022)
Third Prize, Hospital Science and Technology Innovation Award, Chinese Hospital Association (Ranked 7/15) (2021)
Completion with Honors / Top Performing Trainee, University of New York (2021)
Second Prize, Peking University Teaching Achievement Award (Ranked 4/16) (2021)
Second Prize, Peking University Health Science Center Teaching Achievement Award (Ranked 4/16) (2021)
Third Prize, Science and Technology Award, Chinese Pharmaceutical Association (Ranked 10/20) (2020)
Third Prize, Science and Technology Award, Chinese Pharmaceutical Association (Ranked 6/14) (2018)
Academic Innovation Award, Peking University (2018)
Third Prize, Teaching Achievement Award, Peking University Health Science Center (Ranked 3/8) (2017)
Outstanding Teaching Team, Peking University Health Science Center (2017)
Outstanding Clinical Pharmacist, Chinese Society of Clinical Pharmacy (2016)
Outstanding Youth League Cadre, Peking University Health Science Center (2015)
Outstanding Teacher, Peking University Third Hospital (2014)
2011–2024: Recipient of Excellent Paper Awards at the Chinese Pharmaceutical Congress, National Hospital Pharmacy Annual Meeting, Chinese Medical Association Medical Education Conference, Chinese Society of Clinical Pharmacy Annual Meeting, National Conference on Therapeutic Drug Monitoring, Beijing Pharmaceutical Society Annual Meeting, Forbidden City International Pharmacists Congress, and others
REPRESENTATIVE PUBLICATIONS
(1) Mu L, Xu J, Ye X, Jiang Y, Yi Z#. Comparative safety signals of dopamine agonists: psychiatric and cardiovascular risks derived from FDA adverse event reporting system (FAERS) data. BMC Pharmacol Toxicol. 2025;26(1):54.
(2)Li W, Zhang H, Zhang Y, Wang K, Hui J, Yi Z#. Comparison of the effectiveness, safety, and costs of anti-Parkinson drugs: Amultiple-center retrospective study. CNS Neurosci Ther. 2024 30(4):e14531.
(3)Ma Y, Song Z, Li X, Jiang D, Zhao R#, Yi Z#. Toward Genetic Testing of Rivaroxaban? Insights from a Systematic Review on the Role of Genetic Polymorphism in Rivaroxaban Therapy. Clin Pharmacokinet. 2024 63(3):279-291.
(4)Yi Z*#, Mao Y*, He C, Zhang Y, Zhou J, Feng XL#. Medication adherence and costs of medical care among patients with Parkinson's disease: an observational study using electronic medical records. BMC Public Health. 2024 24(1):1202.
(5) Li X*, Song Z*, Yi Z *, Qin J, Jiang D, Wang Z, Li H, Zhao R#. Therapeutic drug monitoring guidelines in oncology: what do weknow and how to move forward? Insights from a systematic review. Ther Adv Med Oncol. 2024 16:17588359241250130.
(6) Li CX, Sun LC, Wang YQ, Liu TT, Cai JR, Liu H, Ren Z, Yi Z#. The associations of candidate gene polymorphisms with aspirinresistance in patients with ischemic disease: a meta-analysis. Hum Genomics. 2024 18(1):135.
(7)Wang R, Li X, Gu X, Cai Q, Wang Y, Yi Z#, Chen LC. The impact of China's zero markup drug policy on drug costs for managing Parkinson's disease and its complications: an interrupted time series analysis. Front Public Health. 2023 9(11):59119.
(8) Yi Z*, Li X, Wang Z, Qin J, Jiang D, Tian P, Yang P, Zhao R#. Status and Quality of Guidelines for Therapeutic Drug Monitoring Based on AGREE II Instrument. Clin Pharmacokinet. 2023 Sep;62(9):1201-1217.
(9)Wang K, Liu ZH, Li XY, Li YF, Li JR, Hui JJ, Li JX, Zhou JW, Yi Z#. Efficacy and safety of selegiline for the treatment of Parkinson's disease: A systematic review and meta-analysis. Front Aging Neurosci. 2023 15:1134472.
(10) Wang Q*, Wu ZY, Tang HL, Yi ZM#, Zhai SD#. The efficacy and safety of prophylactic antibiotics for post-acute stroke infection: A systematic review and meta-analysis. Br J Clin Pharmacol. 2023;89(3):946-955.